THE SHORT ANSWER
What did STEP 1 show?
In adults with overweight or obesity without diabetes, semaglutide plus lifestyle intervention reduced body weight more than placebo over 68 weeks.
The important limitation
This is a trial-specific conclusion. It does not predict an individual result or cover every formulation.
ONE STEP DEEPER
Open the evidence.
See how the study was designed and where its findings apply.
KEEP THE SCOPE IN VIEW
Safety & regulatory context.
In STEP 1, nausea and diarrhea were common, and gastrointestinal events led some participants to stop treatment. See the source for adverse-event details.
No approval status is inferred from a compound name. Jurisdiction, formulation, indication, and a dated primary source are needed for a regulatory entry.
How to read safety & statusCHECK THE ORIGINAL RESEARCH
Sources you can inspect.
- 01
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH et al. · New England Journal of Medicine · 2021
- 02
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Wilding JPH et al. · Diabetes, Obesity and Metabolism · 2022
A VISIBLE RECORD
What changed here?
The extension population is now explicit.
A demonstration of added study context beside an unchanged conclusion.
Open the change record